Press Releases BioCorRx Inc.

Equities

BICX

US09073C2052

Market Closed - OTC Markets Other stock markets 18:15:42 06/05/2024 BST			5-day change	1st Jan Change
0.78 ^USD	+4.00%		+4.00%	0.00%

04-03	BioCorRx Inc. Announces Board Resignations	CI
04-01	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia	04-03	AQ
BioCorRx Reports Business Update for 2023	04-02	AQ
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD	02-28	AQ
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors	02-08	AQ
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President	01-09	AQ
BioCorRx : Material Agreement - Form 8-K	12-15	PU
BioCorRx Reports Business Update for the Third Quarter of 2023	11-14	AQ
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder	15/08/23	AQ
BioCorRx Reports Business Update for the Second Quarter of 2023	14/08/23	AQ
BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder	18/07/23	AQ
BioCorRx Provides Business Update for the First Quarter of 2023	16/05/23	AQ
BIOCORRX INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	11/04/23	AQ
BIOCORRX INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	05/04/23	AQ
BioCorRx Provides Business Update for 2022	03/04/23	AQ
BIOCORRX INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	31/03/23	AQ
BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting	07/03/23	AQ
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data	23/02/23	AQ
BioCorRx to Present at Sequire Biotechnology Conference on February 2nd	30/01/23	AQ
BioCorRx to Present at Sequire Biotechnology Conference on February 2nd	27/01/23	AQ
BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors	24/01/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BioCorRx Inc.

Equities

BICX

US09073C2052

Press Releases

Filters